Direct-acting antiviral therapies for hepatitis c genotype 1 infection: A multiple treatment comparison meta-analysis

QJM: An International Journal of Medicine

Volumn 106, Issue 2, 2013, Pages 153-163

  Cooper, C ^a   Lester, R ^b   Thorlund, K ^c   Druyts, E ^d   El khoury, A C ^e   Yaya, S ^d   Mills, E J ^c,d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR;

ANEMIA; ANTIVIRAL THERAPY; ARTICLE; DRUG EFFICACY; DRUG ERUPTION; HEPATITIS C; HUMAN; META ANALYSIS; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RELAPSE; TREATMENT OUTCOME;

EID: 84873840448     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcs214     Document Type: Article

References (46)

1. Poordad F, Khungar V. Emerging therapeutic options in hepatitis C virus infection. Am J Manag Care 2011; 17(Suppl. 4):S123-30.
2. Ciesek S, Manns MP. Hepatitis in 2010: the dawn of a new era in HCV therapy. Nat Rev Gastroenterol Hepatol 2011; 8:69-71.
3. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
4. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-38.
5. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376:705-16.
6. Poordad F, McCone J, Bacon B, Bruno S, Manns M, Sulkowski M, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-206.
7. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-28.
8. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-17.
9. Flamm S, Lawitz E, Jacobson I, Rubin R, Bourliere M, Hezode C, et al. High sustained virological response (SVR) among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir (BOC) plus peginterferon alfa-2a/ribavirin. J Hepatol 2011; 54:S535-46.
10. Cooper NJ, Peters J, Lai MC, Juni P, Wandel S, Palmer S, et al. How valuable are multiple treatment comparison methods in evidence-based health-care evaluation? Value Health 2011; 14:371-80.
11. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23:3105-24.
12. Sutton A, Ades AE, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008; 26:753-67.
13. Sutton AJ, Higgins JP. Recent developments in meta-analysis. Stat Med 2008; 27:625-50.
14. Ascione A, De Luca M, Tartaglione M, Lampasi F, Di Costanzo G, Lanza A, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138:116-22.
15. Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, et al. Randomized study of peginterferon-alpha 2a plus ribavirin vs peginterferon-alpha 2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010; 138:108-15.
16. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361:580-93.
17. Scotto G, Fazio V, Fornabaio C, Tartaglia A, Di Tullio R, Saracino A, et al. Peg-interferon alpha-2a versus peginterferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study. J Interferon Cytokine Res 2008; 28:623-9.
18. Scotto G, Fazio V, Fornabaio C, Tartaglia A, Di Tullio R, Saracino A, et al. Early and sustained virological response in non-responders with chronic hepatitis C-a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b. Drugs 2008; 68:791-801.
19. Yenice N, Mehtap O, Gumrah M, Arican N. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turk J Gastroenterol 2006; 17:94-8.
20. Garg V, van Heeswijk R, Lee J, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54:20-7.
21. Guedj J, Perelson A. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 2011; 53:1801-8.
22. Adiwijaya B, Hare B, Caron P, Randle J, Neumann A, Reesink H, et al. Rapid decrease of wild-type hepatitis C virus on telaprevir treatment. Antivir Ther 2009; 14:591-5.
23. Susser S, Welsch C, Wang Y, Zettler M, Domingues F, Karey U, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50:1709-18.
24. Curry S, Qiu P, Tong X. Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay. J Virol Methods 2008; 153:156-62.
25. Gelderblom H, Zeuzem S, Weegink C, Forestier N, Mcnair L, Purdy S, et al. Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3.4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a. Scand J Gastroenterol 2008; 43:1122-7.
26. Lawitz E, Rodriguez-Torres M, Muir A, Kieffer T, McNair L, Khunvichai A, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008; 49:163-9.
27. Forestier N, Reesink H, Weegink C, McNair L, Kieffer T, Chu H, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46:640-8.
28. Kieffer T, Sarrazin C, Miller J, Welker M, Forestier N, Reesink H, et al. Telaprevir and pegylated interferon-alpha- 2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46:631-9.
29. Sarrazin C, Kieffer T, Bartels D, Hanzelka B, Müh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132:1767-77.
30. Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta S, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007; 132:1270-8.
31. Reesink H, Zeuzem S, Weegink C, Forestier N, van Vliet A, van de Wetering de Rooij J, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131:997-1002.
32. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56:78-84.
33. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362:1292-303.
34. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-50.
35. Marcellin P, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or-2b to patients with chronic hepatitis C. Gastroenterology 2011; 140:459-68.
36. Muir A, Poordad F, McHutchison J, Shiffman M, Berg T, Ferenci P, et al. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology 2011; 54:1538-46.
37. Sherman K, Flamm S, Afdhal N, Nelson D, Sulkowski M, Everson G, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-24.
38. Foster G, Hézode C, Bronowicki J, Carosi G, Weiland O, Verlinden L, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141:881-9.
39. Antiviral Drugs Advisory Committee, US Food and Drug Administration. Telaprevir, FDA Advisory Committee Briefing Document, April 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM252562.pdf (1 August 2012, date last accessed).
40. Division of Antiviral Products (DAVP), US Food and Drug Administration. Boceprevir, FDA Advisory Committee Briefing Document, April 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/AntiviralDrugsAdvisoryCommittee/ucm252341.pdf (1 August 2012, date last accessed).
41. Cooper CL, Druyts E, Thorlund K, Nachega JB, El Khoury AC, O'Regan C, et al. Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. Ther Clin Risk Manag 2012; 8:105-30.
42. Mills EJ, Ghement I, O'Regan C, Thorlund K. Estimating the power of indirect comparisons: a simulation study. PLOS One 2011; 6:e16237.
43. Druyts E, Mills EJ, Nachega J, O'Regan C, Cooper CL. Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. Clin Exp Gastroenterol 2012; 5:11-21.
44. Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010; 340:c117.
45. Mills E, Bansback N, Ghement I, Thorlund K, Kelly S, Puhan M, et al. Multiple treatment comparison metaanalyses: a step forward into complexity. Clin Epidemiol 2011; 3:193-202.
46. Song F, Xiong T, Parekh-Bhurke S, Loke YK, Sutton AJ, Eastwood AJ, et al. Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. BMJ 2011; 343:d4909.